



Demographics and socioeconomic

| | |
|--|----------|
| Total Population (in 1000) (2020) | 4,314.77 |
| Population <1 year of age (in 1000) (2020) | 77.32 |
| Population 1 year of age (in 1000) (2020) | 77.79 |
| Population <5 years of age (in 1000) (2020) | 389.31 |
| Women of childbearing age (in 1000) (2020) | 3,353.63 |
| Infant Mortality Rate (per 1000 live births) (2017) | 14.0 |
| Gross national income (US\$ per capita) current value (2020) | 11,880.0 |
| National Health Expenditure Public (2018) | 4.6 |
| National Health Expenditure Private (2018) | 2.6 |

Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 2020-2024.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 8 times in 2020.
- 100% of spending on routine immunization is financed using government funds.
- 100% of spending on vaccine purchases is financed using government funds.
- A national nominal electronic immunization registry is in place.


Vaccine Introduction

| | Year |
|--------------------------------------|------|
| Bacterial Meningitis | |
| <i>Haemophilus influenzae</i> type b | 2000 |
| Hepatitis B | 1999 |
| HPV | 2008 |
| Influenza | 2005 |
| MMR1 | 1992 |
| MMR2 | 1992 |
| Pentavalent | 2000 |
| Pneumococcal Conjugate | 2010 |
| Rotavirus | 2006 |
| Tdap | 2008 |
| Tetavalent DPT-Hib or DPT-HepB | |
| Yellow Fever | 1974 |

Immunization Schedule

| PAN | Doses | | | | | |
|---------------------|--------|--------|-----|-----|----|-------|
| | 1 | 2 | 3 | 4 | 5 | 6 |
| BCG | B | | | | | |
| HepB pediatric | B | | | | | |
| DTP-Hib | | | | M18 | | |
| DTP-Hib-HepB | | | | | | |
| DTP-Hib-IPV | | | | | | |
| DTP-Hib-HepB-IPV | M2 | M4 | M6 | | | |
| DTP | | | | | Y4 | |
| Influenza pediatric | M6-M59 | Y5-Y19 | | | | |
| IPV | | | | M18 | Y4 | |
| OPV | | | | M18 | Y4 | |
| MMR | M12 | M18 | | | | |
| Pneumoco conjugate | M2 | M4 | M12 | | | |
| Rotavirus | M2 | M4 | | | | |
| Td | >=Y6 | >=Y6 | | | Y7 | |
| Tdap | | | | | | >=Y10 |
| HPV | | | | | | |

Vaccination Coverage



Surveillance indicators

Acute flaccid paralysis (AFP) - (CARPHA) 2020


| | |
|---|------|
| Number of AFP suspected cases | 11 |
| AFP rate per 100,000 population <15 years old | 0.96 |
| % of cases with 1 adequate samples | 100 |
| % of cases investigated within <48 hours | 45 |
| % sites reporting | 86 |

Measles-rubella (MR) - (CARPHA) 2020


| | |
|--|-----|
| Number of MR suspected cases | 30 |
| % of cases with adequate investigation | 100 |
| % of cases with adequate blood samples | 97 |
| % of samples received in laboratory <=5 days | 67 |
| % of laboratory samples results <=4 days | 90 |




Polio3 coverage and AFP rate per 100,000 children <15 years of age




DTP3 coverage and number of reported diphtheria and pertussis cases




Number of tetanus (no neonatal) and neonatal tetanus cases



Proportion of municipalities by coverage range with DTP3 in children <1 years of age



DTP1-DTP3 and DTP1-MMR1 Dropout Rate



Vaccine Stockout

| PAN | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---------------------|------|------|------|------|------|------|------|------|
| AD syringes | | | | | | | | ● |
| BCG | | ● | | | | | ● | ● |
| Disposable syringes | | | | | | | ● | ● |
| DTP | | | ● | ● | ● | | | ● |
| HepB | | | | | ● | | ● | ● |
| Hib | | | | | | | | ● |
| Influenza | | ● | | | | | | ● |
| IPV | | | ● | ● | ● | ● | | ● |
| Measles | | | | | | | | ● |
| Pneumo. conjugate | | | | ● | | | ● | ● |
| Polio | | | | ● | ● | ● | ● | ● |
| Reconst. syringes | | | | | | | ● | ● |
| Rotavirus | | | | | | | | ● |
| Safety boxes | | | | | | | ● | ● |
| Tdap | | | | | | ● | ● | ● |
| TT | | ● | ● | ● | | | ● | ● |
| Yellow fever | | | | | | | | ● |

Legend

- NB/nb-newborn
- M/m-month
- Y/y-year
- WCBA-women of childbearing age
- with stockout
- no stockout
- no data available